+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Buyang Huanwu Decoction ameliorates ischemic stroke by modulating multiple targets with multiple components: In vitro evidences

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Buyang Huanwu Decoction (BYHWD) is a well-known traditional Chinese medicine prescription which is used to treat ischaemic stroke and stroke-induced disabilities. However, the exact mechanism underlying BYHWD's amelioration of ischaemic stroke and its effective constituents remain unclear. The present study aimed to identify the effective constituents of BYHWD and to further explore its action mechanisms in the amelioration of ischaemic stroke by testing the activities of 15 absorbable chemical constituents of BYHWD with the same methods under the same conditions. The following actions of these 15 compounds were revealed: 1) Ferulic acid, calycosin, formononetin, astrapterocarpan-3- O-β-D-glucoside, paeonol, calycosin-7- O-β-D-glucoside, astraisofla-van-7- O-β-D-glucoside, ligustrazine, and propyl gallate significantly suppressed concanavalin A (Con A)-induced T lymphocyte proliferation; 2) Propyl gallate, calycosin-7- O-β-D-glucoside, paeonol, and ferulic acid markedly inhibited LPS-induced apoptosis in RAW264.7 cells; 3) Propyl gallate and formononetin significantly inhibited LPS-induced NO release; 4) Hydroxysafflor yellow A and inosine protected PC12 cells against the injuries caused by glutamate; and 5) Formononetin, astragaloside IV, astraisoflavan-7- O-β-D-glucoside, inosine, paeoniflorin, ononin, paeonol, propyl gallate, ligustrazine, and ferulic acid significantly suppressed the constriction of the thoracic aorta induced by KCl in rats. In conclusion, the results from the present study suggest that BYHWD exerts its ischaemic stroke ameliorating activities by modulating multiple targets with multiple components.

          Related collections

          Author and article information

          Chinese Journal of Natural Medicines
          20 March 2018
          : 16
          : 3
          : 194-202
          1Department of Molecular and Cellular Pharmacology, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China
          2Department of Clinical Pharmacy, Beijing Tsinghua Changgung Hospital Medical Center, Tsinghua University, Beijing 102218, China
          3State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing 100191, China
          Author notes
          Corresponding authors: YE Jia, Tel: 86-10-82802653, Fax: 86-10-82802653, E-mail: yejia@

          ΔThese authors contributed equally to this work.

          These authors have no conflict of interest to declare.

          Copyright © 2018 China Pharmaceutical University. Published by Elsevier B.V. All rights reserved.
          Funded by: National Natural Science Foundation of China
          Award ID: 81470050
          Funded by: Beijing Natural Science Foundation
          Award ID: 7122097
          This work was supported by National Natural Science Foundation of China (No. 81470050) and Beijing Natural Science Foundation (No. 7122097).


          Comment on this article